By Julia Karow
RainDance Technologies and Ambry Genetics have launched ADMESeq, a targeted sequencing panel that will sequence 242 genes involved with drug absorption, distribution, metabolism, and excretion.
By Julia KarowThis article has been updated from a previous version to attribute Ambry's comments to the company's assistant medical director.
By a GenomeWeb staff reporter
Ambry Genetics will be the first authorized service provider for a new high-throughput target enrichment system being developed by RainDance Technologies, the companies announced last week.
By Justin Petrone
Growing demand for arrays designed to detect tumor copy-number changes is enticing more chip manufacturers to offer tools tailor-made for cancer research.
Ambry Genetics last week launched its CancerArray, an exon-focused, 180,000-probe array for comparative genomic hybridization.
Ambry's StemArray is manufactured by Roche NimbleGen and enables researchers studying stem cells to detect genomic abnormalities that would ordinarily be missed by low-resolution karyotyping.
CLG will sell the StemArray products and services to its current customers and other companies and research institutions.
Ambry Genetics is now able to offer all Roche NimbleGen applications, the first of Roche NimbleGen's growing list of service providers to achieve such certification.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.